Abstracts tagged "Cutaneous manifestations and vasculitis"

Abstract Number: 1934 • 2016 ACR/ARHP Annual Meeting
Cutaneous Manifestations of ANCA-Associated Vasculitis
Zelma ChiesaFuxench¹, Robert Micheletti², Raashid Luqmani³, Richard Watts⁴, Anthea Craven⁵ and Peter A. Merkel⁶, ¹University of Pennsylvania, Philadelphia, PA, ²Department of Dermatology, Hospital of the University of Pennsylvania, Philadelphia, PA, ³Oxford, Oxford, United Kingdom, ⁴Norwich Medical School, University of East Anglia, Norwich, United Kingdom, ⁵Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford, United Kingdom, ⁶Division of Rheumatology, University of Pennsylvania, Philadelphia, PA
The cutaneous manifestations of anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV), including granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA), are varied…
Abstract Number: 2389 • 2012 ACR/ARHP Annual Meeting
Cutaneous Leukocytoclastic Angiitis: Study of 173 Patients
Javier Loricera¹, Vanesa Calvo-Rio¹, Francisco Ortiz-Sanjuan¹, Marcos Antonio Gonzalez-Lopez², Hector Fernandez-Llaca³, Javier Rueda-Gotor⁴, Carmen Gonzalez-Vela⁵, Miguel A. Gonzalez-Gay⁴ and Ricardo Blanco⁴, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IFIMAV. Santander. Spain, Santander, Spain, ²Dermatology, Hospital Universitario Marqués de Valdecilla. IFIMAV, Santander, Spain, ³Dermatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, ⁴Rheumatology, Hospital Universitario Marqués de Valdecilla. IFIMAV, Santander, Spain, ⁵Pathology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain
Background/Purpose: Cutaneous leukocytoclastic angiitis (CLA) was defined by the International Consensus Conference for the Nomenclature of the Vasculitis (Chapel Hill, A&R 1994) as an isolated…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].